AIMD Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions has a net margin of -15991.17% compared to Ainos's net margin of -370.29%. Ainos's return on equity of -52.95% beat Intelligent Bio Solutions's return on equity of -164.63%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 943.48%. Given that Intelligent Bio Solutions has higher upside potential than Ainos, analysts believe Intelligent Bio Solutions is more attractive than Ainos.

Ainos has a beta of 1.832, which suggesting that the stock is 83.213% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Intelligent Bio Solutions quarterly revenues of $607.5K. Ainos's net income of -$4.7M is lower than Intelligent Bio Solutions's net income of -$2.2M. Notably, Ainos's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 50.03x versus 1.32x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -15991.17% compared to Ainos's net margin of -72.93%. Ainos's return on equity of -52.95% beat Standard BioTools's return on equity of -36.54%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 130.58%. Given that Standard BioTools has higher upside potential than Ainos, analysts believe Standard BioTools is more attractive than Ainos.

Ainos has a beta of 1.832, which suggesting that the stock is 83.213% more volatile than S&P 500. In comparison Standard BioTools has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.101%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Standard BioTools quarterly revenues of $46.7M. Ainos's net income of -$4.7M is higher than Standard BioTools's net income of -$34.1M. Notably, Ainos's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 50.03x versus 2.09x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -15991.17% compared to Ainos's net margin of -111.78%. Ainos's return on equity of -52.95% beat LENSAR's return on equity of -134.77%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 11.61%. Given that LENSAR has higher upside potential than Ainos, analysts believe LENSAR is more attractive than Ainos.

Ainos has a beta of 1.832, which suggesting that the stock is 83.213% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than LENSAR quarterly revenues of $16.7M. Ainos's net income of -$4.7M is higher than LENSAR's net income of -$18.7M. Notably, Ainos's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 50.03x versus 2.89x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Movano has a net margin of -15991.17% compared to Ainos's net margin of -14402%. Ainos's return on equity of -52.95% beat Movano's return on equity of --.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Movano has an analysts' consensus of -- which suggests that it could grow by 2614.93%. Given that Movano has higher upside potential than Ainos, analysts believe Movano is more attractive than Ainos.

Ainos has a beta of 1.832, which suggesting that the stock is 83.213% more volatile than S&P 500. In comparison Movano has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Movano pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Movano quarterly revenues of $50K. Ainos's net income of -$4.7M is higher than Movano's net income of -$7.2M. Notably, Ainos's price-to-earnings ratio is -- while Movano's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 50.03x versus -- for Movano. Usually stocks with elevated PS ratios are considered overvalued.